Hormone replacement therapy - reviewing the evidence

September 19, 2002

A rapid review article in this week's issue of THE LANCET weighs up the current evidence for the health outcomes of hormone replacement therapy (HRT) use. The review--which includes data from the recently published Womens Health Initiative (WHI) study--provides consistent evidence to refute the widely held view that HRT may be protective against coronary heart disease. The review also points to the consistent evidence across trials suggesting that HRT use is associated with an increased risk of stroke.

HRT has been used increasingly across western populations since the early 1990s--an estimated 20 million women in western countries were using HRT at the end of the past decade. Around a third of women in their fifties in the UK use HRT for an average of five years, with a similar proportion in the rest of Europe. The impact of HRT on health outcomes has been widely debated, with suggestions that HRT use may increase the risk of certain cancers--notably breast cancer--while also being protective against osteoporosis and coronary heart disease.

Valerie Beral and colleagues from Cancer Research UK's Epidemiology Unit, Oxford, UK, reviewed the existing data on the effects of HRT on seven life-threatening conditions--largely based on data from four randomised trials, one involving an oestrogen-only treatment, the others using a combined oestrogen/progestagen combination--to provide an up-to-date analysis of the long-term effects of HRT use.

Evidence from the four HRT trials (which included over 20,000 women followed up for around five years) showed that HRT users are at an increased relative risk of breast cancer, pulmonary embolism (blood clot in the lung), and stroke, compared with women given placebo.

HRT was found to be protective against colorectal cancer and hip fracture. There were no significant differences in the risks of endometrial cancer or coronary heart disease, and not enough data to assess the relationship between HRT use and rarer diseases such as ovarian cancer. They estimated that for healthy women in their fifties, use of HRT for five years would cause an extra breast cancer, stroke, or pulmonary embolism in 6 in every 1000 users, but reduce the incidence of colorectal cancer and hip fracture by 1.7 in every 1000--giving on balance an overall increase in one of these conditions of 4.3 out of every 1000 HRT users (1 in 250). For women in their sixties, the overall increase is 6.5 in every 1000 HRT users (1 in 150). Breast cancer was the most prominent negative health outcome among users in their fifties, which shifted to cardiovascular disease among women in their sixties.

Valerie Beral comments: "These estimates provide a rough guide to the likely overall change in the incidence of these conditions over a 5 year period for typical healthy HRT users in western countries. Each woman would, understandably, give different weight to the importance of each condition, as well as to the relief of menopausal symptoms."
-end-
Contact:
Professor Valerie Beral,
c/o Cancer Research UK Press Office

Sally Staples,
Cancer Research UK,
61 Lincoln's Inn Fields, London WC2A 3PX, UK;
T) +44 (0)20 7061 6045;
F) +44 (0)20 7935 1546;
E) sally.staples@cancer.org.uk

Lancet

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.